BioMarin's reported revenue reaccelerated to roughly $1.0B in Q3 2026, up 32.0% year over year, suggesting renewed top-line momentum after a softer 2025.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue reached roughly $1.0B in Q3 2026 with 32.0% year-over-year growth, but operating margin compressed to -8.0% as SG&A rose to $333.6M, against a peak operating margin of 33.5% in Q2 2025.
BioMarin Pharmaceutical Inc. (BMRN) receives extensive stock analysis, price targets, and earnings estimates, indicating strong investor interest and market visibility.
With offices and facilities in the United States, South America, Asia, and Europe, BioMarin has a diversified global footprint, enhancing its market reach and operational resilience.
BioMarin's focus on responsible operations, efficiency improvements, and environmental impact reduction aligns with growing investor demand for sustainable and ethical business practices.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 2, 2026 | $0.23+566.2% vs -$0.05 | $1.0B+0.2% vs $1.0B |
Q3 2026 Aug 6, 2026 | $1.20+26.7% vs $0.95 | $990M+6.2% vs $932M |
Q2 2026 May 4, 2026 | $0.76-2.6% vs $0.78 | $766M+1.8% vs $753M |
Q1 2026 Feb 23, 2026 | -$0.24-241.7% vs $0.17 | $875M+4.9% vs $834M |
Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 17,538 shares of the biotechnology company's stock, valued at approximately $1,052,000. Other hedge funds and other institutional investors also recently added to
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an increase of approximately 228% compared to the typical daily volume of 1,206 call options. BioMarin Pharmaceutical News Summary Here are the key news stories impacting
BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.
Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
Benchmark BMRN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioMarin Pharmaceutical Inc. (BMRN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — |
BioMarin Pharmaceutical Inc. (BMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioMarin Pharmaceutical Inc. (BMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 2, 2026·SEC
Oct 6, 2026·SEC
Aug 6, 2026·SEC
Get notified when BMRN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioMarin Pharmaceutical Inc. (BMRN) stock FAQ — growth, dividends, profitability & financials explained
BioMarin Pharmaceutical Inc. (BMRN) reported $3.66B in revenue over the trailing twelve months. Revenue was $3.22B in fiscal year 2025. That is 268338% more than the $1.2M of fiscal year 1998.
BioMarin Pharmaceutical Inc. (BMRN) grew revenue by 18.1% over the trailing twelve months, compared with the twelve months before.
No. BioMarin Pharmaceutical Inc. (BMRN) reported a net loss of $19.1M over the trailing twelve months.
BioMarin Pharmaceutical Inc. (BMRN) had a return on equity (ROE) of -0.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
BioMarin Pharmaceutical Inc. (BMRN) generated $557.9M in free cash flow over the trailing twelve months.
